Gut microbiome signatures distinguish type 2 diabetes mellitus from non-alcoholic fatty liver disease. 2021

Jiyeon Si, and Giljae Lee, and Hyun Ju You, and Sae Kyung Joo, and Dong Hyeon Lee, and Bon Jeong Ku, and Seoyeon Park, and Won Kim, and GwangPyo Ko
Medical Science Research Institute, School of Medicine, Sungkyunkwan University (SKKU), Suwon 16419, Republic of Korea.

Non-alcoholic fatty liver disease (NAFLD) is closely associated with type 2 diabetes mellitus (T2D), and these two metabolic diseases demonstrate bidirectional influences. The identification of microbiome profiles that are specific to liver injury or impaired glucose metabolism may assist understanding of the role of the gut microbiota in the relationship between NAFLD and T2D. Here, we studied a biopsy-proven Asian NAFLD cohort (n = 329; 187 participants with NAFLD, 101 with NAFLD and T2D, and 41 with neither) and identified Enterobacter, Romboutsia, and Clostridium sensu stricto as the principal taxa associated with the severity of NAFLD and T2D, whereas Ruminococcus and Megamonas were specific to NAFLD. In particular, the taxa that were associated with both severe liver pathology and T2D were also significantly associated with markers of diabetes, such as fasting blood glucose and Hb1Ac. Enterotype analysis demonstrated that participants with NAFLD had a significantly higher proportion of Bacteroides and a lower proportion of Ruminococcus than a Korean healthy twin cohort (n = 756). However, T2D could not be clearly distinguished from NAFLD. Analysis of an independent T2D cohort (n = 185) permitted us to validate the T2D-specific bacterial signature identified in the NAFLD cohort. Functional inference analysis revealed that endotoxin biosynthesis pathways were significantly enriched in participants with NAFLD and T2D, compared with those with NAFLD alone. These findings may assist with the development of effective therapeutic approaches for metabolic diseases that are associated with specific bacterial signatures.

UI MeSH Term Description Entries

Related Publications

Jiyeon Si, and Giljae Lee, and Hyun Ju You, and Sae Kyung Joo, and Dong Hyeon Lee, and Bon Jeong Ku, and Seoyeon Park, and Won Kim, and GwangPyo Ko
January 2022, Progress in molecular biology and translational science,
Jiyeon Si, and Giljae Lee, and Hyun Ju You, and Sae Kyung Joo, and Dong Hyeon Lee, and Bon Jeong Ku, and Seoyeon Park, and Won Kim, and GwangPyo Ko
May 2022, Orvosi hetilap,
Jiyeon Si, and Giljae Lee, and Hyun Ju You, and Sae Kyung Joo, and Dong Hyeon Lee, and Bon Jeong Ku, and Seoyeon Park, and Won Kim, and GwangPyo Ko
May 2022, Orvosi hetilap,
Jiyeon Si, and Giljae Lee, and Hyun Ju You, and Sae Kyung Joo, and Dong Hyeon Lee, and Bon Jeong Ku, and Seoyeon Park, and Won Kim, and GwangPyo Ko
January 2023, Annals of hepatology,
Jiyeon Si, and Giljae Lee, and Hyun Ju You, and Sae Kyung Joo, and Dong Hyeon Lee, and Bon Jeong Ku, and Seoyeon Park, and Won Kim, and GwangPyo Ko
October 2022, Journal of clinical and translational hepatology,
Jiyeon Si, and Giljae Lee, and Hyun Ju You, and Sae Kyung Joo, and Dong Hyeon Lee, and Bon Jeong Ku, and Seoyeon Park, and Won Kim, and GwangPyo Ko
July 2014, World journal of gastroenterology,
Jiyeon Si, and Giljae Lee, and Hyun Ju You, and Sae Kyung Joo, and Dong Hyeon Lee, and Bon Jeong Ku, and Seoyeon Park, and Won Kim, and GwangPyo Ko
March 2021, Journal of personalized medicine,
Jiyeon Si, and Giljae Lee, and Hyun Ju You, and Sae Kyung Joo, and Dong Hyeon Lee, and Bon Jeong Ku, and Seoyeon Park, and Won Kim, and GwangPyo Ko
January 2023, Current diabetes reviews,
Jiyeon Si, and Giljae Lee, and Hyun Ju You, and Sae Kyung Joo, and Dong Hyeon Lee, and Bon Jeong Ku, and Seoyeon Park, and Won Kim, and GwangPyo Ko
September 2020, Experimental and therapeutic medicine,
Jiyeon Si, and Giljae Lee, and Hyun Ju You, and Sae Kyung Joo, and Dong Hyeon Lee, and Bon Jeong Ku, and Seoyeon Park, and Won Kim, and GwangPyo Ko
March 2017, Hepatology research : the official journal of the Japan Society of Hepatology,
Copied contents to your clipboard!